Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

France's Mauna Kea eyes surgical technology partnership by end 2015

Published 2015-11-13, 10:38 a/m
© Reuters. France's Mauna Kea eyes surgical technology partnership by end 2015
ISRG
-
MDT
-
NDQ
-
ALMKT
-
7733
-

PARIS, Nov 13 (Reuters) - French medical technology company
Mauna Kea MKEA.PA could sign a partnership by the end of the
year that would allow it to accelerate the commercial
development of a small microscope approved by U.S. regulators
for use in surgical procedures to diagnose cancer, its chief
executive told Reuters.
Cellvizio provides images of cells and helps doctors
diagnose cancers of the stomach, oesophagus and bile ducts.
Mauna Kea's shares jumped almost 60 percent in a single day
after it was approved by the U.S. Food and Drug Administration.
"We can now address another market, minimally invasive
surgery, which has a number of players offering a range of
potential uses for our technology", Sacha Loiseau, founder and
chief executive of the company, said.
According to Mauna Kea, the use of Cellvizio in surgery
would give it access to a market worth between 400 million and 1
billion euros ($1.1 billion) a year.
Loiseau lists U.S. firms Stryker SKY.N , Medtronic (N:MDT) MDT.N ,
Intuitive Surgical ISRG.O , Japan's Olympus 7733.T , Germany's
Storz and Canada's Novadaq NDQ.TO as surgical market players
he would be "potentially interested" in working with.
"We think we could integrate our Cellvizio technology into
their platforms. We are quite confident that we will announce a
deal by the end of the year", he added.
Loiseau said it was "quite possible" the company would turn
to financial markets to raise funds when it had presented its
road map to investors, adding this "could be in 2016."
($1 = 0.9305 euros)

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.